Skip to main content

Genome Editing and the Future of Personalized and Targeted Cancer Medicine

vchalup / stock.adobe.com © vchalup / stock.adobe.com

Many human diseases, including cancer, have their etiology in genome alterations. Completion of the human genome project and the development of next generation sequencing technologies with single cell resolution will lead to routine complete genome mapping of cancer patients in the future. Genome editing is based on unique properties shared by mega-nucleases, zinc-finger nucleases, transcription activator-like effector nucleases, and the CRISPR/Cas9 system and their ability to generate cuts in the human genome at specific targeted sites thereby allowing replacement of defective DNA with a corrected sequence. Although still in its infancy, these technologies have the potential to revolutionize medicine and patient care.

Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.

  1. Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure. As a reversible epigenet...

    Authors: Zaoqu Liu, Haijiao Zou, Qin Dang, Hui Xu, Long Liu, Yuyuan Zhang, Jinxiang Lv, Huanyun Li, Zhaokai Zhou and Xinwei Han
    Citation: Molecular Cancer 2022 21:220
  2. Brain cancer is regarded among the deadliest forms of cancer worldwide. The distinct tumor microenvironment and inherent characteristics of brain tumor cells virtually render them resistant to the majority of ...

    Authors: Xuchen Qi, Saurabh Kumar Jha, Niraj Kumar Jha, Saikat Dewanjee, Abhijit Dey, Rahul Deka, Pingal Pritam, Kritika Ramgopal, Weiting Liu and Kaijian Hou
    Citation: Molecular Cancer 2022 21:204
  3. Chimeric fusion transcription factors are oncogenic hallmarks of several devastating cancer entities including pediatric sarcomas, such as Ewing sarcoma (EwS) and alveolar rhabdomyosarcoma (ARMS). Despite thei...

    Authors: Tilman L. B. Hölting, Florencia Cidre-Aranaz, Dana Matzek, Bastian Popper, Severin J. Jacobi, Cornelius M. Funk, Florian H. Geyer, Jing Li, Ignazio Piseddu, Bruno L. Cadilha, Stephan Ledderose, Jennifer Zwilling, Shunya Ohmura, David Anz, Annette Künkele, Frederick Klauschen…
    Citation: Molecular Cancer 2022 21:199
  4. In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress a...

    Authors: Nastasja Merle, Sabrina Elmshäuser, Florian Strassheimer, Michael Wanzel, Alexander M. König, Julianne Funk, Michelle Neumann, Katharina Kochhan, Frederik Helmprobst, Axel Pagenstecher, Andrea Nist, Marco Mernberger, André Schneider, Thomas Braun, Tilman Borggrefe, Rajkumar Savai…
    Citation: Molecular Cancer 2022 21:191
  5. Lung cancer is one of the fatal cancers worldwide, and over 60% of patients are lung adenocarcinoma (LUAD). Our clinical data demonstrated that DNA methylation of the promoter region of miR-126-3p was upregula...

    Authors: Lu Liang, Huiyu Cen, Jionghua Huang, Aiping Qin, Wenyan Xu, Siran Wang, Zhijun Chen, Lin Tan, Qiqi Zhang, Xiyong Yu, Xin Yang and Lingmin Zhang
    Citation: Molecular Cancer 2022 21:186
  6. Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptio...

    Authors: I. Garces de los Fayos Alonso, L. Zujo, I. Wiest, P. Kodajova, G. Timelthaler, S. Edtmayer, M. Zrimšek, S. Kollmann, C. Giordano, M. Kothmayer, H. A. Neubauer, S. Dey, M. Schlederer, B. S. Schmalzbauer, T. Limberger, C. Probst…
    Citation: Molecular Cancer 2022 21:172
  7. Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new prec...

    Authors: Junfeng Jiang, Yuanyuan Chen, Li Zhang, Qishu Jin, Liujun Wang, Sha Xu, Kexin Chen, Li Li, Tao Zeng, Xingfei Fan, Tingting Liu, Jiaxi Li, Jinjiang Wang, Chaofeng Han, Fu Gao, Yanyong Yang…
    Citation: Molecular Cancer 2022 21:164
  8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered u...

    Authors: Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, Xin Luan, Zhengbo Song, Xiangdong Cheng, Weidong Zhang and Jiang-Jiang Qin
    Citation: Molecular Cancer 2022 21:159
  9. Cancer is a type of malignant affliction threatening human health worldwide; however, the molecular mechanism of cancer pathogenesis remains to be elusive. The oncogenic hedgehog (Hh) pathway is a highly evolu...

    Authors: Jia Song, Yuexin Ge, Xiaoyu Sun, Qiutong Guan, Shiqiang Gong, Minjie Wei, Jumin Niu and Lin Zhao
    Citation: Molecular Cancer 2022 21:115
  10. The tumor microenvironment (TME) is essential for immune escape by tumor cells. It plays essential roles in tumor development and metastasis. The clinical outcomes of tumors are often closely related to indivi...

    Authors: Ke Liu, Jia-Jia Cui, Yan Zhan, Qian-Ying Ouyang, Qi-Si Lu, Dong-Hua Yang, Xiang-Ping Li and Ji-Ye Yin
    Citation: Molecular Cancer 2022 21:98
  11. Cancer is caused by a combination of genetic and epigenetic abnormalities. Current cancer therapies are limited due to the complexity of their mechanism, underlining the need for alternative therapeutic approa...

    Authors: Sushmaa Chandralekha Selvakumar, K. Auxzilia Preethi, Kehinde Ross, Deusdedit Tusubira, Mohd Wajid Ali Khan, Panagal Mani, Tentu Nageswara Rao and Durairaj Sekar
    Citation: Molecular Cancer 2022 21:83
  12. CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) shows the opportunity to treat a diverse array of untreated various genetic and complicated disorders. Therapeutic g...

    Authors: Mohammed Fatih Rasul, Bashdar Mahmud Hussen, Abbas Salihi, Bnar Saleh Ismael, Paywast Jamal Jalal, Anna Zanichelli, Elena Jamali, Aria Baniahmad, Soudeh Ghafouri-Fard, Abbas Basiri and Mohammad Taheri
    Citation: Molecular Cancer 2022 21:64
  13. Clustered regularly interspaced short palindromic repeats (CRISPR) system provides adaptive immunity against plasmids and phages in prokaryotes. This system inspires the development of a powerful genome engine...

    Authors: Si-Wei Wang, Chao Gao, Yi-Min Zheng, Li Yi, Jia-Cheng Lu, Xiao-Yong Huang, Jia-Bin Cai, Peng-Fei Zhang, Yue-Hong Cui and Ai-Wu Ke
    Citation: Molecular Cancer 2022 21:57
  14. The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance. The genes th...

    Authors: Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen…
    Citation: Molecular Cancer 2022 21:37
  15. In recent years, the application of functional genetic immuno-oncology screens has showcased the striking ability to identify potential regulators engaged in tumor-immune interactions. Although these screens h...

    Authors: Yan Li, Chen Yang, Zhicheng Liu, Shangce Du, Susan Can, Hailin Zhang, Linmeng Zhang, Xiaowen Huang, Zhenyu Xiao, Xiaobo Li, Jingyuan Fang, Wenxin Qin, Chong Sun, Cun Wang, Jun Chen and Huimin Chen
    Citation: Molecular Cancer 2022 21:2
  16. The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the development of the Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease9 (CRI...

    Authors: Huimin Zhang, Chunhong Qin, Changming An, Xiwang Zheng, Shuxin Wen, Wenjie Chen, Xianfang Liu, Zhenghua Lv, Pingchang Yang, Wei Xu, Wei Gao and Yongyan Wu
    Citation: Molecular Cancer 2021 20:126